Skip to main content

Advertisement

SpringerLink
Log in

Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

To determine the effect of phytotherapy (Serona repens) on the clinical progression in men with mild symptoms of bladder outlet obstruction (BOO). A total of 189 patients with mild symptoms of BOO, recruited from four different European clinics, were included in the analysis. Age, prostate specific antigen (PSA), international prostate symptom score (IPSS), quality of life (QOL), maximum urinary flow rate (Qmax) and total prostate and transitional zone volume were recorded. Clinical progression was defined as change from the mild-IPSS group into the moderate or severe group or the occurrence of urinary retention and need of surgery. Cumulative progression rate was 1, 7, 9 and 16% at 6, 12, 18 and 24 month, respectively, for the active group (Serona repens) as compared to 6, 13, 15 and 24% for the watchful waiting group. (P=0.03) significant improvements in the Qmax, IPSS and QOL were seen in the group receiving Serona repens. Serona repens significantly reduced the clinical progression rates in men with mild symptoms of BOO. It also led to improvements in urinary symptoms, QOL scores and urinary flow rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Oishi K, Boyle P, Barry MJ (1998) Epidemiology and natural history of BPH. In: Denis L, Murphy G, Khoury S (eds) 3rd International consultation on BPH. Jersy, Scientific Communications International

  2. Welsch G, Weinger K, Barry MJ (2000) Quality-of-life impact of lower urinary tract symptom severity: results from the health professionals follow-up study. Urology 59:245–250

    Article  Google Scholar 

  3. Girman CJ, Jacobsen SJ, Tsukamoto T, Richard F, Garraway WM, Sagnier PP, Guess HA, Rhodes T, Boyle P, Lieber MM (1998) Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 51:428–436

    Article  PubMed  CAS  Google Scholar 

  4. McConnell JD, Barry MJ, Bruskewitz RC (1994) Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guideline, number 8. AHCPR publication no. 94-0582. Rockville, MD, Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services

  5. Djavan B, Wammack R, Dobrovits M, Bagheri F, Kramer G, Hruby S, Chaudry A, Andreas Reissigl, Alexandre Zlotta, Marberger M (2002) Predictors of progression in men with mild symptoms of bladder outlet obstruction. J Urol 167(Suppl):268, A1054

    Google Scholar 

  6. Marwick C (1995) Growing use of medicinal botanicals forces assessment by drug regulators. JAMA 273:607–609

    Article  PubMed  CAS  Google Scholar 

  7. Astin JA (1998) Why patients use alternative medicine: results of a national study. JAMA 279:1548–1553

    Article  PubMed  CAS  Google Scholar 

  8. Furnham A, Forey J (1994) The attitudes, behaviors, and beliefs of patients of conventional vs complementary (alternative) medicine. J Clin Psychol 50:458–469

    Article  PubMed  CAS  Google Scholar 

  9. Descotes JL, Rambeaud JJ, Deschaseaux P (1995) Placebo controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug invest 9:291–297

    Article  Google Scholar 

  10. Cukier J, Ducasso J, Le Guillou M (1999) Permixon versus placebo. Results from multicenter trial. CR Ther Pharmacol Clin 4:15–21

    Google Scholar 

  11. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1098 patients. Prostate 29:231–240

    Article  PubMed  Google Scholar 

  12. Grasso M, Montesano A, Buonaguidi A, Castelli M, Lania C, Rigatti P, Rocco F, Cesana BM, Borghi C (1995) Comparative effects of alfuzosin versus Serona repens in the treatment of benign prostate hyperplasia. Arch Esp Urol 48:97–103

    PubMed  CAS  Google Scholar 

  13. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD (2001) Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 58:960–965

    Article  PubMed  CAS  Google Scholar 

  14. McConnell JD, Roehrborn CG, Baustita OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM (2003) The long-term effect on doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–1398

    Article  PubMed  CAS  Google Scholar 

  15. Boyle P, Robertson C, Lowe F, Roehtborn C (2000) Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 55:533–539

    Article  PubMed  CAS  Google Scholar 

  16. Kaplan SA, Goluboff ET, Olsson CA, Deverka PA, Chmiel JJ (1995) Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology 5:398–405

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Vienna, AKH Ebene 8D, Wahringer Gurtel 18-20, 1090, Wien, Austria

    Bob Djavan, Yan Kit Fong, Theodore Anagnostou, Matthias Waldert, Sibylle Marihart, Mike Harik & Michael Marberger

  2. Department of Urology, St Thomas Hospital, London, UK

    Aziz Chaudry

  3. Department of Urology, LKH Bregenz, Bregenz, Austria

    Andreas Reissigl

  4. Department of Urology, Unversity Pecz, Budaphest, Hungary

    Fariborz Bagheri

Authors
  1. Bob Djavan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Kit Fong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aziz Chaudry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andreas Reissigl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Theodore Anagnostou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fariborz Bagheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Matthias Waldert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sibylle Marihart
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mike Harik
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michael Marberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bob Djavan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Djavan, B., Fong, Y.K., Chaudry, A. et al. Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting. World J Urol 23, 253–256 (2005). https://doi.org/10.1007/s00345-005-0005-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-005-0005-7

Keywords

Search

Navigation